The Pharma Letter7 天
ITM achieves milestone radiopharm Phase III triumph
Privately-held Isotope Technologies Munich (ITM) has presented attention-grabbing positive Phase III results from a ...
BioSpace1 天
Pfizer Sees Path to Braftovi’s Full Approval With Phase III CRC Data
Topline data on a combo including Pfizer’s kinase inhibitor Braftovi point to improved progression-free survival and pave the ...
Forbes1 年
As The Regulatory Landscape Shifts Globally, So, Too, Must The Pharma Commercial Model
In 2011, the country enacted the Pharmaceutical Market Reform Act ... as opposed to progression free survival (PFS), which had been previously used as a measure of value. Recently, Germany ...
Vincerx Pharma, Inc. and Oqory, Inc. Highlight Promising Data for Oqory’s TROP2 Antibody ...
Companies also provide insights into proposed strategic mergerSAN MATEO, Calif., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Vincerx ...